Boston Scientific receives EU approval for platinum chromium stent system

14 May 2010

Boston Scientific Corporation (NYSE:BSX) has received CE Mark approval for its Taxus Element Paclitaxel-Eluting Coronary Stent System, the Company's third-generation drug-eluting stent (DES) technology.

This approval includes a specific indication for the treatment of diabetic patients. The system incorporates a platinum chromium alloy with an innovative stent design and an advanced catheter delivery system. The Company plans to launch it next month in the European Union and other CE Mark countries.

"In my experience, the platinum chromium alloy and new stent design used in the Taxus Element Stent offer increased flexibility, visibility and deliverability," said Dean Kereiakes, M.D., Medical Director at The Christ Hospital Heart and Vascular Center and The Lindner Research Center in Cincinnati and the Principal Investigator for the PERSEUS clinical program.

"The Element platform represents a significant advance in coronary stenting with performance improvements that could simplify procedures and allow treatment of a broader range of patients. The combination of the proven Taxus drug and polymer with the new Element platform provides a welcome treatment option."

"As the worldwide prevalence of diabetes continues to increase dramatically, the diabetic indication for the TAXUS Element Stent System represents an important benefit for diabetic patients being treated for coronary artery disease," said Hank Kucheman, Executive Vice President and Group President, Cardiology, Rhythm and Vascular for Boston Scientific. "The Taxus Element Stent System, with the proven performance of paclitaxel, provides an advanced treatment option for diabetic patients. This product's unique mechanism of action helps to inhibit restenosis in high-risk patients with diabetes, and we are pleased to offer it to these patients."

The Taxus Element Stent is designed specifically for coronary stenting and leverages the performance advantages of the Element platform with a decade of clinical success from the Taxus program. The novel stent architecture and proprietary platinum chromium alloy combine to offer greater radial strength and flexibility. The stent architecture helps create consistent lesion coverage and drug distribution while improving deliverability, which is enhanced by an advanced catheter delivery system. The higher density alloy provides superior visibility and reduced recoil while permitting thinner struts compared to prior-generation stents (1).

The Company received CE Mark approval for the Promus Element Everolimus-Eluting Stent System in October 2009. Both Element systems incorporate the same platinum chromium alloy, innovative stent design and advanced catheter delivery system.

In the US, the Company expects FDA approval for the Taxus Element Stent System in mid 2011 and for the PROMUS Element Stent System in mid 2012. In Japan, the Company expects approval for the Taxus Element Stent System in late 2011 or early 2012 and for the Promus Element Stent System in mid 2012.

To top